In an era of skyrocketing health-care costs and finite financial resources, health economists are increasingly called upon to determine which medical treatments are the most cost-effective. Now two researchers suggest a way to tailor this cost-benefit analysis (more accurately known as an incremental cost-effectiveness ratio, or ICER) more precisely to individuals by assessing the outcome of each treatment on smaller subgroups of patients.